Aerosol delivery of siRNA to the lungs. part 1: Rationale for gene delivery systems

KONA Powder and Particle Journal

Volumn 2016, Issue 33, 2016, Pages 63-85

  Youngren Ortiz, Susanne R ^a   Gandhi, Nishant S ^a   España Serrano, Laura ^a   Chougule, Mahavir B ^a,b  

^a UNIVERSITY OF HAWAII AT HILO   (United States)

^b UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

Aerosolization; Lung; Nanocarrier; Nanoparticle; Pulmonary; SiRNA

Indexed keywords

BIOLOGICAL ORGANS; DOPPLER EFFECT; GENE TRANSFER; MAGNETIC RESONANCE IMAGING; NANOPARTICLES; NUCLEAR MEDICINE; PULMONARY DISEASES; RNA;

AEROSOLIZATION; LUNG; NANOCARRIERS; PULMONARY; SIRNA;

AEROSOLS;

EID: 84957081772     PISSN: 02884534     EISSN: 21875537     Source Type: Journal    
DOI: 10.14356/kona.2016014     Document Type: Review

References (207)

1. Adamcakova-Dodd A., Stebounova L.V., Kim J.S., Vorrink S.U., Ault A.P., O'shaughnessy P.T., Grassian V.H., Thorne P.S., Toxicity assessment of zinc oxide nanoparticles using subacute and sub-chronic murine inhalation models, Part Fibre Toxicol, 11 (2014) b1.
2. Adams K.E., Ke S., Kwon S., Liang F., Fan Z., Lu Y., Hirschi K., Mawad M.E., Barry M.A., Sevick-Muraca E.M., Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer, Journal of biomedical optics, 12 (2007) 024017-024017-024019.
3. Agrawal N., Dasaradhi P., Mohmmed A., Malhotra P., Bhatnagar R.K., Mukherjee S.K., RNA interference: Biology, mechanism, and applications, Microbiology and molecular biology reviews, 67 (2003) 657-685.
4. Agu R.U., Ugwoke M.I., Armand M., Kinget R., Verbeke N., The lung as a route for systemic delivery of therapeutic proteins and peptides, Respiratory research, 2 (2001) 198.
5. Amarzguioui M., Rossi J.J., Kim D., Approaches for chemically synthesized siRNA and vector-mediated RNAi, FEBS Letters, 579 (2005) 5974-5981.
6. Amatngalim G.D., Van Wijck Y., De Mooij-Eijk Y., Verhoosel R.M., Harder J., Lekkerkerker A.N., Janssen R.A., Hiemstra P.S., Basal cells contribute to innate immunity of the airway epithelium through production of the antimicrobial protein rnase 7, J Immunol, 194 (2015) 3340-3350.
7. Ari A., Jet, ultrasonic, and mesh nebulizers: An evaluation of nebulizers for better clinical outcomes (2014).
8. Ari A., Hess D., Myers T., Rau J., A guide to aerosol delivery devices for respiratory therapists, Dallas, Texas: American Association for Respiratory Care (2009).
9. Ari A., Restrepo R.D., Aerosol delivery device selection for spontaneously breathing patients: 2012, Respiratory care, 57 (2012) 613-626.
10. Arnold M.M., Gorman E.M., Schieber L.J., Munson E.J., Berkland C., NanoCipro encapsulation in monodisperse large porous PLGA microparticles, Journal of Controlled Release, 121 (2007) 100-109.
11. Arunthari V., Bruinsma R.S., Lee A.S., Johnson M.M., A prospective, comparative trial of standard and breath-actuated nebulizer: Efficacy, safety, and satisfaction, Respiratory care, 57 (2012) 1242-1247.
12. Bai S., Gupta V., Ahsan F., Inhalable lactose-based dry powder formulations of low molecular weight heparin, Journal of aerosol medicine and pulmonary drug delivery, 23 (2010) 97-104.
13. Bally M.B., Harvie P., Wong F.M., Kong S., Wasan E.K., Reimer D.L., Biological barriers to cellular delivery of lipid-based DNA carriers, Advanced drug delivery reviews, 38 (1999) 291-315.
14. Bastacky J., Lee C., Goerke J., Koushafar H., Yager D., Kenaga L., Speed T.P., Chen Y., Clements J.A., Alveolar lining layer is thin and continuous: Low-temperature scanning electron microscopy of rat lung, Journal of Applied Physiology, 79 (1995) 1615-1628.
15. Ben-Jebria A., Eskew M.L., Edwards D.A., Inhalation system for pulmonary aerosol drug delivery in rodents using large porous particles, Aerosol Science & Technology, 32 (2000) 421-433.
16. Bisgaard H., O'callaghan C., Smaldone G.C., Drug delivery to the lung, CRC Press, 2001.
17. Bitko V., Musiyenko A., Shulyayeva O., Barik S., Inhibition of respiratory viruses by nasally administered siRNA, Nature medicine, 11 (2005) 50-55.
18. Bivas-Benita M., Zwier R., Junginger H.E., Borchard G., Non-invasive pulmonary aerosol delivery in mice by the endotracheal route, European Journal of Pharmaceutics and Biopharmaceutics, 61 (2005) 214-218.
19. Bondesson E., Bengtsson T., Borgström L., Nilsson L.-E., Norrgren K., Trofast E., Wollmer P., Planar gamma scintigraphy-points to consider when quantifying pulmonary dry powder aerosol deposition, International journal of pharmaceutics, 258 (2003) 227-240.
20. Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., Behr J.-P., A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine, Proceedings of the National Academy of Sciences, 92 (1995) 7297-7301.
21. Burnett J.C., Rossi J.J., RNA-based therapeutics: Current progress and future prospects, Chemistry & biology, 19 (2012) 60-71.
22. Burns A.R., Smith C.W., Walker D.C., Unique structural features that influence neutrophil emigration into the lung, 2003.
23. Carvalho T.C., Peters J.I., Williams Iii R.O., Influence of particle size on regional lung deposition-what evidence is there?, International Journal of Pharmaceutics, 406 (2011) 1-10.
24. Chakravarty R., Hong H., Cai W., Positron emission tomography image-guided drug delivery: Current status and future perspectives, Molecular pharmaceutics, 11 (2014) 3777-3797.
25. Chan H.-K., Formulation challenges: Protein powders for inhalation, Drugs and the Pharmaceutical Sciences, 126 (2003) 879-890.
26. Chan H.-K., Eberl S., Glover W., Radiolabeling of pharmaceutical aerosols and gamma scintigraphic imaging for lung deposition, Encyclopedia of Pharmaceutical Technology, 3rd ed. Informa Healthcare, New York, (2007) 3094-3107.
27. Chapters U.G., USP <601> Aerosols, nasal sprays, metered-dose inhalers and dry powder inhalers, USP 32-NF (2009).
28. Cherry S.R., Gambhir S.S., Use of positron emission tomography in animal research, ILAR journal, 42 (2001) 219-232.
29. Chiang P.-C., Alsup J.W., Lai Y., Hu Y., Heyde B.R., Tung D., Evaluation of aerosol delivery of nanosuspension for pre-clinical pulmonary drug delivery, Nanoscale research letters, 4 (2009) 254-261.
30. Choi S.W., Lee S.H., Mok H., Park T.G., Multifunctional siRNA delivery system: Polyelectrolyte complex micelles of sixarm PEG conjugate of siRNA and cell penetrating peptide with crosslinked fusogenic peptide, Biotechnology progress, 26 (2010) 57-63.
31. Chougule M., Padhi B., Misra A., Development of spray dried liposomal dry powder inhaler of dapsone, AAPS Pharm-SciTech, 9 (2008) 47-53.
32. Codrons V., Vanderbist F., Verbeeck R.K., Arras M., Lison D., Préat V., Vanbever R., Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats, Journal of pharmaceutical sciences, 92 (2003) 938-950.
33. Comsa D.C., Farrell T.J., Patterson M.S., Quantitative fluorescence imaging of point-like sources in small animals, Physics in medicine and biology, 53 (2008) 5797.
34. Conde J., Tian F., Hernandez Y., Bao C., Cui D., Janssen K.P., Ibarra M.R., Baptista P.V., Stoeger T., De La Fuente J.M., In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models, Biomaterials, 34 (2013) 7744-7753.
35. Conway J., Lung imaging-two dimensional gamma scintigraphy, SPECT, CT and PET, Advanced drug delivery reviews, 64 (2012) 357-368.
36. Cryan S.-A., Sivadas N., Garcia-Contreras L., In vivo animal models for drug delivery across the lung mucosal barrier, Advanced drug delivery reviews, 59 (2007) 1133-1151.
37. Dailey L.A., Schmehl T., Gessler T., Wittmar M., Grimminger F., Seeger W., Kissel T., Nebulization of biodegradable nanoparticles: Impact of nebulizer technology and nanoparticle characteristics on aerosol features, Journal of Controlled Release, 86 (2003) 131-144.
38. Dalby R., Spallek M., Voshaar T., A review of the development of respimat® soft mistTM inhaler, International journal of pharmaceutics, 283 (2004) 1-9.
39. Dames P., Gleich B., Flemmer A., Hajek K., Seidl N., Wiekhorst F., Eberbeck D., Bittmann I., Bergemann C., Weyh T., Trahms L., Rosenecker J., Rudolph C., Targeted delivery of magnetic aerosol droplets to the lung, Nat Nanotechnol, 2 (2007) 495-499.
40. Davies N.M., Feddah M.R., A novel method for assessing dissolution of aerosol inhaler products, International journal of pharmaceutics, 255 (2003) 175-187.
41. Daviskas E., Anderson S.D., Jaques A., Charlton B., Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis, CHEST Journal, 137 (2010) 861-868.
42. De Boer A.H., Gjaltema D., Hagedoorn P., Frijlink H.W., Characterization of inhalation aerosols: A critical evaluation of cascade impactor analysis and laser diffraction technique, Int J Pharm, 249 (2002) 219-231.
43. De Fougerolles A., Novobrantseva T., SiRNA and the lung: Research tool or therapeutic drug?, Current opinion in pharmacology, 8 (2008) 280-285.
44. De Fougerolles A., Vornlocher H.-P., Maraganore J., Lieberman J., Interfering with disease: A progress report on siRNA-based therapeutics, Nat Rev Drug Discov, 6 (2007) 443-453.
45. Denyer J., Dyche T., The adaptive aerosol delivery (AAD) technology: Past, present, and future, Journal of aerosol medicine and pulmonary drug delivery, 23 (2010) S-1-S-10.
46. Denyer J., Nikander K., Smith N., Adaptive aerosol delivery (AAD®) technology, Expert opinion on drug delivery, 1 (2004) 165-176.
47. Devincenzo J., Cehelsky J.E., Alvarez R., Elbashir S., Harborth J., Toudjarska I., Nechev L., Murugaiah V., Van Vliet A., Vaishnaw A.K., Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV), Antiviral research, 77 (2008) 225-231.
48. Devincenzo J., Lambkin-Williams R., Wilkinson T., Cehelsky J., Nochur S., Walsh E., Meyers R., Gollob J., Vaishnaw A., A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus, Proceedings of the National Academy of Sciences, 107 (2010) 8800-8805.
49. Dhand R., Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol, Respiratory care, 47 (2002) 1406-1416; discussion 1416-1408.
50. Dickinson P.A., Howells S.W., Kellaway I.W., Novel nanoparticles for pulmonary drug administration, Journal of drug targeting, 9 (2001) 295-302.
51. Dolovich M.B., 18f-fluorodeoxyglucose positron emission tomographic imaging of pulmonary functions, pathology, and drug delivery, Proceedings of the American Thoracic Society, 6 (2009) 477-485.
52. Dolovich M.B., Dhand R., Aerosol drug delivery: Developments in device design and clinical use, The Lancet, 377 (2011) 1032-1045.
53. Driscoll K.E., Costa D.L., Hatch G., Henderson R., Oberdorster G., Salem H., Schlesinger R.B., Intratracheal instillation as an exposure technique for the evaluation of respiratory tract toxicity: Uses and limitations, Toxicological Sciences, 55 (2000) 24-35.
54. Dunbar C., Mitchell J., Analysis of cascade impactor mass distributions, Journal of Aerosol Medicine-Deposition Clearance and Effects in the Lung, 18 (2005) 439-451.
55. Eberl S., Chan H.-K., Daviskas E., SPECT imaging for radioaerosol deposition and clearance studies, Journal of aerosol medicine, 19 (2006) 8-20.
56. Edwards D.A., Hanes J., Caponetti G., Hrkach J., Ben-Jebria A., Eskew M.L., Mintzes J., Deaver D., Lotan N., Langer R., Large porous particles for pulmonary drug delivery, Science, 276 (1997) 1868-1872.
57. Elhissi A., Karnam K.K., Danesh-Azari M.R., Gill H.S., Taylor K.M., Formulations generated from ethanol-based proliposomes for delivery via medical nebulizers, Journal of pharmacy and pharmacology, 58 (2006) 887-894.
58. Elhissi A., Taylor K., Delivery of liposomes generated from proliposomes using air-jet, ultrasonic, and vibrating-mesh nebulisers, Journal of drug delivery science and technology, 15 (2005) 261-265.
59. Eshel G., Levy G., Mingelgrin U., Singer M., Critical evaluation of the use of laser diffraction for particle-size distribution analysis, Soil Science Society of America Journal, 68 (2004) 736-743.
60. Everard M.L., Studies using radiolabelled aerosols in children, Thorax, 49 (1994) 1259-1266.
61. Feddah M.R., Brown K.F., Gipps E.M., Davies N.M., In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: Influence of inspiratory flow rates, J Pharm Pharm Sci, 3 (2000) 318-324.
62. Fellmann C., Lowe S.W., Stable RNA interference rules for silencing, Nature cell biology, 16 (2014) 10-18.
63. Fernandes C.A., Vanbever R., Preclinical models for pulmonary drug delivery, Expert opinion on drug delivery, 6 (2009) 1231-1245.
64. Ferrari S., Kitson C., Farley R., Steel R., Marriott C., Parkins D., Scarpa M., Wainwright B., Evans M., Colledge W., Mucus altering agents as adjuncts for nonviral gene transfer to airway epithelium, Gene therapy, 8 (2001) 1380-1386.
65. Fire A., Xu S.Q., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C., Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans, Nature, 391 (1998) 806-811.
66. Fleming J., Conway J., Majoral C., Tossici-Bolt L., Katz I., Caillibotte G., Perchet D., Pichelin M., Muellinger B., Martonen T., The use of combined single photon emission computed tomography and X-ray computed tomography to assess the fate of inhaled aerosol, Journal of aerosol medicine and pulmonary drug delivery, 24 (2011) 49-60.
67. Frauenfelder T., Kestenholz P., Hunziker R., Nguyen T.D.L., Fries M., Veit-Haibach P., Husmann L., Stahel R., Weder W., Opitz I., Use of computed tomography and positron emission tomography/computed tomography for staging of local extent in patients with malignant pleural mesothelioma, Journal of computer assisted tomography, 39 (2015) 160-165.
68. Fulton A., Peters S.T., Perkins G.A., Jarosinski K.W., Damiani A., Brosnahan M., Buckles E.L., Osterrieder N., Van De Walle G.R., Effective treatment of respiratory alphaherpesvirus infection using RNA interference, PLoS One, 4 (2009) e4118.
69. Garbuzenko O.B., Saad M., Betigeri S., Zhang M., Vetcher A.A., Soldatenkov V.A., Reimer D.C., Pozharov V.P., Minko T., Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug, Pharmaceutical Research, 26 (2009) 382-394.
70. Ghosn B., Singh A., Li M., Vlassov A.V., Burnett C., Puri N., Roy K., Efficient gene silencing in lungs and liver using imidazole-modified chitosan as a nanocarrier for small interfering RNA, Oligonucleotides, 20 (2010) 163-172.
71. Greene C.M., Mcelvaney N.G., Proteases and antiproteases in chronic neutrophilic lung disease-relevance to drug discovery, British journal of pharmacology, 158 (2009) 1048-1058.
72. Groneberg D., Eynott P., Lim S., Oates T., Wu R., Carlstedt I., Roberts P., Mccann B., Nicholson A., Harrison B., Expression of respiratory mucins in fatal status asthmaticus and mild asthma, Histopathology, 40 (2002) 367-373.
73. Gunther M., Lipka J., Malek A., Gutsch D., Kreyling W., Aigner A., Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung, Eur J Pharm Biopharm, 77 (2011) 438-449.
74. Gutbier B., Kube S.M., Reppe K., Santel A., Lange C., Kaufmann J., Suttorp N., Witzenrath M., RNAi-mediated suppression of constitutive pulmonary gene expression by small interfering RNA in mice, Pulmonary pharmacology & therapeutics, 23 (2010) 334-344.
75. Hannon G.J., RNA interference, Nature, 418 (2002) 244-251.
76. Hanson L.R., Frey W.H., 2nd, Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease, BMC Neurosci, 9 Suppl 3 (2008) S5.
77. Haynes J.M., Randomized controlled trial of a breath-activated nebulizer in patients with exacerbation of COPD, Respira tory care, 57 (2012) 1385-1390.
78. Heyder J., Gebhart J., Rudolf G., Schiller C.F., Stahlhofen W., Deposition of particles in the human respiratory tract in the size range 0.005-15 μm, Journal of Aerosol Science, 17 (1986) 811-825.
79. Hibbitts A., O'mahony A.M., Forde E., Nolan L., Ogier J., Desgranges S., Darcy R., Macloughlin R., O'driscoll C.M., Cryan S.A., Early-stage development of novel cyclodextrin-siRNA nanocomplexes allows for successful postnebulization transfection of bronchial epithelial cells, J Aerosol Med Pulm Drug Deliv, 27 (2014) 466-477.
80. Hickey A.J., Pharmaceutical inhalation aerosol technology, CRC Press, 2003.
81. TMin Therapeutic Drug Carrier Systems, 18 (2001).
82. Hill D.B., Vasquez P.A., Mellnik J., Mckinley S.A., Vose A., Mu F., Henderson A.G., Donaldson S.H., Alexis N.E., Boucher R.C., A biophysical basis for mucus solids concentration as a candidate biomarker for airways disease, PloS one, 9 (2014) e87681.
83. Hinchcliffe M., Illum L., Intranasal insulin delivery and therapy, Adv Drug Deliv Rev, 35 (1999) 199-234.
84. Ho S.L., Kwong W.J., O'drowsky L., Coates A.L., Evaluation of four breath-enhanced nebulizers for home use, Journal of aerosol medicine, 14 (2001) 467-475.
85. TMinhaler and pressurized metered dose inhalers, Journal of aerosol medicine, 18 (2005) 273-282.
86. Hosoya K., Satoh T., Yamamoto Y., Saeki K., Igawa K., Okano M., Moriya T., Imamura O., Nemoto Y., Yokozeki H., Gene silencing of STAT6 with siRNA ameliorates contact hypersensitivity and allergic rhinitis, Allergy, 66 (2011) 124-131.
87. Howard K.A., Rahbek U.L., Liu X., Damgaard C.K., Glud S.Z., Andersen M.O., Hovgaard M.B., Schmitz A., Nyengaard J.R., Besenbacher F., Kjems J., RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system, Mol Ther, 14 (2006) 476-484.
88. Huchon G.J., Montgomery A.B., Lipavsky A., Hoeffel J.M., Murray J.F., Respiratory clearance of aerosolized radioactive solutes of varying molecular weight, Journal of nuclear medicine: official publication, Society of Nuclear Medicine, 28 (1987) 894-902.
89. Kamei N., Takeda-Morishita M., Brain delivery of insulin boosted by intranasal coadministration with cell-penetrating peptides, J Control Release, 197 (2015) 105-110.
90. Kanasty R., Dorkin J.R., Vegas A., Anderson D., Delivery materials for siRNA therapeutics, Nature materials, 12 (2013) 967-977.
91. Khalil I.A., Kogure K., Akita H., Harashima H., Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery, Pharmacological reviews, 58 (2006) 32-45.
92. Kim D.H., Rossi J.J., Strategies for silencing human disease using RNA interference, Nature Reviews Genetics, 8 (2007) 173-184.
93. Kishore U., Greenhough T.J., Waters P., Shrive A.K., Ghai R., Kamran M.F., Bernal A.L., Reid K.B., Madan T., Chakraborty T., Surfactant proteins SP-A and SP-D: Structure, function and receptors, Mol Immunol, 43 (2006) 1293-1315.
94. Knowles M.R., Boucher R.C., Mucus clearance as a primary innate defense mechanism for mammalian airways, The Journal of clinical investigation, 109 (2002) 571-577.
95. Kolaczkowska E., Kubes P., Neutrophil recruitment and function in health and inflammation, Nat Rev Immunol, 13 (2013) 159-175.
96. Komlosi P., Altes T.A., Qing K., Mooney K.E., Miller G.W., Mata J.F., De Lange E.E., Tobias W.A., Cates G.D., Brookeman J.R., Regional anisotropy of airspace orientation in the lung as assessed with hyperpolarized helium-3 diffusion MRI, Journal of Magnetic Resonance Imaging (2015).
97. Koping-Hoggard M., Issa M.M., Kohler T., Tronde A., Varum K.M., Artursson P., A miniaturized nebulization catheter for improved gene delivery to the mouse lung, J Gene Med, 7 (2005) 1215-1222.
98. Kovar J.L., Simpson M.A., Schutz-Geschwender A., Olive D.M., A systematic approach to the development of fluorescent contrast agents for optical imaging of mouse cancer models, Analytical biochemistry, 367 (2007) 1-12.
99. Kruger S.J., Niles D.J., Dardzinski B., Harman A., Jarjour N.N., Ruddy M., Nagle S.K., Francois C.J., Sorkness R.L., Burton R.M., Hyperpolarized helium-3 MRI of exercise-induced bronchoconstriction during challenge and therapy, Journal of Magnetic Resonance Imaging, 39 (2014) 1230-1237.
100. Kuroki Y., Takahashi M., Nishitani C., Pulmonary collectins in innate immunity of the lung, Cellular microbiology, 9 (2007) 1871-1879.
101. Kusumoto K., Akita H., Ishitsuka T., Matsumoto Y., Nomoto T., Furukawa R., El-Sayed A., Hatakeyama H., Kajimoto K., Yamada Y., Kataoka K., Harashima H., Lipid envelope-type nanoparticle incorporating a multifunctional peptide for systemic siRNA delivery to the pulmonary endothelium, ACS Nano, 7 (2013) 7534-7541.
102. Lam J.K.-W., Liang W., Chan H.-K., Pulmonary delivery of therapeutic siRNA, Advanced drug delivery reviews, 64 (2012) 1-15.
103. Laube B.L., The expanding role of aerosols in systemic drug delivery, gene therapy and vaccination: An update, Translational Respiratory Medicine, 2 (2014) 1-12.
104. Lebhardt T., Roesler S., Beck-Broichsitter M., Kissel T., Polymeric nanocarriers for drug delivery to the lung, Journal of Drug Delivery Science and Technology, 20 (2010) 171-180.
105. Lee Black D., Mcquay M.Q., Bonin M.P., Laser-based techniques for particle-size measurement: A review of sizing methods and their industrial applications, Progress in Energy and Combustion Science, 22 (1996) 267-306.
106. Lee S.H., Kim S.H., Park T.G., Intracellular siRNA delivery system using polyelectrolyte complex micelles prepared from VEGF siRNA-PEG conjugate and cationic fusogenic peptide, Biochemical and biophysical research communications, 357 (2007) 511-516.
107. Lentz Y.K., Anchordoquy T.J., Lengsfeld C.S., Rationale for the selection of an aerosol delivery system for gene delivery, Journal of aerosol medicine, 19 (2006) 372-384.
108. Li B.-J., Tang Q., Cheng D., Qin C., Xie F.Y., Wei Q., Xu J., Liu Y., Zheng B.-J., Woodle M.C., Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in rhesus macaque, Nature medicine, 11 (2005) 944-951.
109. Luo Y., Zhai X., Ma C., Sun P., Fu Z., Liu W., Xu J., An inhalable beta(2)-adrenoceptor ligand-directed guanidinylated chitosan carrier for targeted delivery of siRNA to lung, J Control Release, 162 (2012) 28-36.
110. Mainelis G., Seshadri S., Garbuzenko O., Han T., Wang Z., Minko T., Characterization and application of a nose-only exposure chamber for inhalation delivery of liposomal drugs and nucleic acids to mice, Journal of aerosol medicine and pulmonary drug delivery, 26 (2013) 345-354.
111. Majoral C., Fleming J., Conway J., Katz I., Tossici-Bolt L., Pichelin M., Montesantos S., Caillibotte G., Controlled, parametric, individualized, 2D and 3D imaging measurements of aerosol deposition in the respiratory tract of healthy human volunteers: In vivo data analysis, Journal of aerosol medicine and pulmonary drug delivery, 27 (2014) 349-362.
112. Mansour H.M., Rhee Y.-S., Wu X., Nanomedicine in pulmonary delivery, International Journal of Nanomedicine, 4 (2009) 299-319.
113. Marsh M., Endocytosis (2001).
114. Martin A.R., Thompson R.B., Finlay W.H., MRI measurement of regional lung deposition in mice exposed nose-only to nebulized superparamagnetic iron oxide nanoparticles, Journal of aerosol medicine and pulmonary drug delivery, 21 (2008) 335-342.
115. Massaro D., Massaro G.D., Clerch L.B., Noninvasive delivery of small inhibitory RNA and other reagents to pulmonary alveoli in mice, American Journal of Physiology-Lung Cellular and Molecular Physiology, 287 (2004) L1066-L1070.
116. Mastrandrea L.D., Quattrin T., Clinical evaluation of inhaled insulin, Advanced drug delivery reviews, 58 (2006) 1061-1075.
117. Maxfield F.R., Mcgraw T.E., Endocytic recycling, Nature reviews Molecular cell biology, 5 (2004) 121-132.
118. Mellnik J., Vasquez P.A., Mckinley S.A., Witten J., Hill D.B., Forest M.G., Micro-heterogeneity metrics for diffusion in soft matter, Soft matter, 10 (2014) 7781-7796.
119. Merkel O.M., Beyerle A., Librizzi D., Pfestroff A., Behr T.M., Sproat B., Barth P.J., Kissel T., Nonviral siRNA delivery to the lung: Investigation of PEG-PEI polyplexes and their in vivo performance, Molecular pharmaceutics, 6 (2009) 1246-1260.
120. Merkel O.M., Rubinstein I., Kissel T., SiRNA delivery to the lung: What's new?, Adv Drug Deliv Rev, 75 (2014) 112-128.
121. Merkel O.M., Zheng M., Debus H., Kissel T., Pulmonary gene delivery using polymeric nonviral vectors, Bioconjug Chem, 23 (2012) 3-20.
122. Merkus H.G., Particle size measurements: Fundamentals, practice, quality, Springer Science & Business Media, 2009.
123. Minne A., Louahed J., Mehauden S., Baras B., Renauld J.C., Vanbever R., The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response, Immunology, 122 (2007) 316-325.
124. Mitchell J.P., Nagel M.W., Cascade impactors for the size characterization of aerosols from medical inhalers: Their uses and limitations, Journal of Aerosol Medicine-Deposition Clearance and Effects in the Lung, 16 (2003) 341.
125. Mitchell J.P., Nagel M.W., Doyle C.C., Ali R.S., Avvakoumova V.I., Christopher J.D., Quiroz J., Strickland H., Tougas T., Lyapustina S., Relative precision of inhaler aerodynamic particle size distribution (APSD) metrics by full resolution and abbreviated andersen cascade impactors (ACIs): Part 1, Aaps Pharmscitech, 11 (2010) 843-851.
126. Morello M., Krone C.L., Dickerson S., Howerth E., Germishuizen W.A., Wong Y.-L., Edwards D., Bloom B.R., Hondalus M.K., Dry-powder pulmonary insufflation in the mouse for application to vaccine or drug studies, Tuberculosis, 89 (2009) 371-377.
127. Morén F., Aerosols in medicine: Principles, diagnosis, and therapy, Elsevier Science Limited, 1993.
128. Morita T., Niwata Y., Ohgi K., Ogawa M., Irie M., Distribution of two urinary ribonuclease-like enzymes in human organs and body fluids, J Biochem, 99 (1986) 17-25.
129. Mosbah K., Ruiz-Cabello J., Berthezene Y., Cremillieux Y., Aerosols and gaseous contrast agents for magnetic resonance imaging of the lung, Contrast media & molecular imaging, 3 (2008) 173-190.
130. Moschos S.A., Jones S.W., Perry M.M., Williams A.E., Erjefalt J.S., Turner J.J., Barnes P.J., Sproat B.S., Gait M.J., Lindsay M.A., Lung delivery studies using siRNA conjugated to TAT (48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity, Bioconjugate chemistry, 18 (2007) 1450-1459.
131. Mühlfeld C., Rothen-Rutishauser B., Blank F., Vanhecke D., Ochs M., Gehr P., Interactions of nanoparticles with pulmonary structures and cellular responses, American Journal of Physiology-Lung Cellular and Molecular Physiology, 294 (2008) L817-L829.
132. Murata M., Tahara K., Takeuchi H., Real-time in vivo imaging of surface-modified liposomes to evaluate their behavior after pulmonary administration, European Journal of Pharmaceutics and Biopharmaceutics, 86 (2014) 115-119.
133. Murata N., Takashima Y., Toyoshima K., Yamamoto M., Okada H., Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice, Journal of Controlled Release, 126 (2008) 246-254.
134. Nahar K., Gupta N., Gauvin R., Absar S., Patel B., Gupta V., Khademhosseini A., Ahsan F., In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals, Eur J Pharm Sci, 49 (2013) 805-818.
135. Najlah M., Parveen I., Alhnan M.A., Ahmed W., Faheem A., Phoenix D.A., Taylor K.M., Elhissi A., The effects of suspension particle size on the performance of air-jet, ultrasonic and vibrating-mesh nebulisers, Int J Pharm, 461 (2014) 234-241.
136. Newman S., Wilding I., Gamma scintigraphy: An in vivo technique for assessing the equivalence of inhaled products, International journal of pharmaceutics, 170 (1998) 1-9.
137. Newman S.P., Pitcairn G.R., Hirst P.H., A brief history of gamma scintigraphy, Journal of Aerosol Medicine, 14 (2001) 139-145.
138. Newman S.P., Pitcairn G.R., Hirst P.H., Rankin L., Radionuclide imaging technologies and their use in evaluating asthma drug deposition in the lungs, Advanced drug delivery reviews, 55 (2003) 851-867.
139. Newman S.P., Wilding I.R., Imaging techniques for assessing drug delivery in man, Pharmaceutical science & technology today, 2 (1999) 181-189.
140. Newman S.P., Wilding I.R., Hirst P.H., Human lung deposition data: The bridge between in vitro and clinical evaluations for inhaled drug products?, International journal of pharmaceutics, 208 (2000) 49-60.
141. Nichols S.C., Mitchell J.P., Shelton C.M., Roberts D.L., Good cascade impactor practice (GCIP) and considerations for "in-use" specifications, Aaps Pharmscitech, 14 (2013) 375-390.
142. Nielsen E.J., Nielsen J.M., Becker D., Karlas A., Prakash H., Glud S.Z., Merrison J., Besenbacher F., Meyer T.F., Kjems J., Howard K.A., Pulmonary gene silencing in transgenic EGFP mice using aerosolised chitosan/siRNA nanoparticles, Pharm Res, 27 (2010) 2520-2527.
143. Ntziachristos V., Culver J.P., Rice B.W., Small-animal optical imaging, Journal of biomedical optics, 13 (2008) 011001-011001-011001.
144. O'shaughnessy P.T., Achutan C., O'neill M.E., Thorne P.S., A small whole-body exposure chamber for laboratory use, Inhalation toxicology, 15 (2003) 251-263.
145. Oliveira S., Van Rooy I., Kranenburg O., Storm G., Schiffelers R.M., Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes, International journal of pharmaceutics, 331 (2007) 211-214.
146. Padhi B.K., Chougule M.B., Misra A., Aerosol performance of large respirable particles of amikacin sulfate produced by spray and freeze drying techniques, Curr Drug Deliv, 6 (2009) 8-16.
147. Park C.-W., Rhee Y.-S., Vogt F.G., Hayes D., Zwischenberger J.B., Deluca P.P., Mansour H.M., Advances in microscopy and complementary imaging techniques to assess the fate of drugs ex vivo in respiratory drug delivery: An invited paper, Advanced drug delivery reviews, 64 (2012) 344-356.
148. Parton R.G., Richards A.A., Lipid rafts and caveolae as portals for endocytosis: New insights and common mechanisms, Traffic, 4 (2003) 724-738.
149. Patel B., Gupta N., Ahsan F., Particle engineering to enhance or lessen particle uptake by alveolar macrophages and to influence the therapeutic outcome, European Journal of Pharmaceutics and Biopharmaceutics, 89 (2015) 163-174.
150. Patel G., Chougule M., Singh M., Misra A., Nanoliposomal dry powder formulations, Methods in enzymology, 464 (2009) 167-191.
151. Patton J.S., Mechanisms of macromolecule absorption by the lungs, Advanced Drug Delivery Reviews, 19 (1996) 3-36.
152. Patton J.S., Brain J.D., Davies L.A., Fiegel J., Gumbleton M., Kim K.J., Sakagami M., Vanbever R., Ehrhardt C., The particle has landed-characterizing the fate of inhaled pharmaceuticals, J Aerosol Med Pulm Drug Deliv, 23 Suppl 2 (2010) S71-87.
153. Perl M., Chung C.-S., Lomas-Neira J., Rachel T.-M., Biffl W.L., Cioffi W.G., Ayala A., Silencing of Fas, but not caspase-8, in lung epithelial cells ameliorates pulmonary apoptosis, inflammation, and neutrophil influx after hemorrhagic shock and sepsis, The American journal of pathology, 167 (2005) 1545-1559.
154. Perring S., Summers Q., Fleming J., Nassim M., Holgate S., A new method of quantification of the pulmonary regional distribution of aerosols using combined CT and SPECT and its application to nedocromil sodium administered by metered dose inhaler, The British journal of radiology, 67 (1994) 46-53.
155. Pettis R.J., Hall I., Costa D., Hickey A.J., Aerosol delivery of muramyl dipeptide to rodent lungs, AAPS PharmSci, 2 (2000) 53-61.
156. Phelps M.E., Positron emission tomography provides molecular imaging of biological processes, Proceedings of the National Academy of Sciences, 97 (2000) 9226-9233.
157. Possmayer F., Nag K., Rodriguez K., Qanbar R., Schürch S., Surface activity in vitro: Role of surfactant proteins, Comparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology, 129 (2001) 209-220.
158. Rawat A., Majumder Q.H., Ahsan F., Inhalable large porous microspheres of low molecular weight heparin: In vitro and in vivo evaluation, Journal of Controlled Release, 128 (2008) 224-232.
159. Reischl D., Zimmer A., Drug delivery of siRNA therapeutics: Potentials and limits of nanosystems, Nanomedicine: Nanotechnology, Biology and Medicine, 5 (2009) 8-20.
160. Rosas-Taraco A.G., Higgins D.M., Sánchez-Campillo J., Lee E.J., Orme I.M., González-Juarrero M., Intrapulmonary delivery of XCL1-targeting small interfering RNA in mice chronically infected with mycobacterium tuberculosis, American journal of respiratory cell and molecular biology, 41 (2009) 136-145.
161. Rose M.C., Nickola T.J., Voynow J.A., Airway mucus obstruction: Mucin glycoproteins, MUC gene regulation and goblet cell hyperplasia, American Journal of Respiratory Cell and Molecular Biology, 25 (2001) 533-537.
162. Ross D.L., Schultz R.K., Effect of inhalation flow rate on the dosing characteristics of dry powder inhaler (DPI) and metered dose inhaler (MDI) products, Journal of aerosol medicine, 9 (1996) 215-226.
163. Roy I., Vij N., Nanodelivery in airway diseases: Challenges and therapeutic applications, Nanomedicine, 6 (2010) 237-244.
164. Rubin B.K., Physiology of airway mucus clearance, Respir Care, 47 (2002) 761-768.
165. Rytting E., Nguyen J., Wang X., Kissel T., Biodegradable polymeric nanocarriers for pulmonary drug delivery, Expert Opin Drug Deliv, 5 (2008) 629-639.
166. Saha G.B., Macintyre W.J., Go R.T., Cyclotrons and positron emission tomography radiopharmaceuticals for clinical imaging, Seminars in nuclear medicine, Elsevier, 1992.
167. Sakagami M., In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery, Advanced drug delivery reviews, 58 (2006) 1030-1060.
168. Sanders N., Rudolph C., Braeckmans K., De Smedt S.C., Demeester J., Extracellular barriers in respiratory gene therapy, Advanced drug delivery reviews, 61 (2009) 115-127.
169. Schuster B.S., Suk J.S., Woodworth G.F., Hanes J., Nanoparticle diffusion in respiratory mucus from humans without lung disease, Biomaterials, 34 (2013) 3439-3446.
170. Seaton B.A., Crouch E.C., Mccormack F.X., Head J.F., Hartshorn K.L., Mendelsohn R., Structural determinants of pattern recognition by lung collectins, Innate Immunity (2010).
171. Senoo T., Hattori N., Tanimoto T., Furonaka M., Ishikawa N., Fujitaka K., Haruta Y., Murai H., Yokoyama A., Kohno N., Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis, Thorax, 65 (2010) 334-340.
172. Seow W.Y., Liang K., Kurisawa M., Hauser C.A., Oxidation as a facile strategy to reduce the surface charge and toxicity of polyethyleneimine gene carriers, Biomacromolecules, 14 (2013) 2340-2346.
173. Shah V.P., Smurthwaite M.J., Veranth J.M., Zaidi K., The inhalation ad hoc advisory panel for the USP performance tests of inhalation dosage forms (2008).
174. Sharma K., Somavarapu S., Colombani A., Govind N., Taylor K.M., Nebulised siRNA encapsulated crosslinked chitosan nanoparticles for pulmonary delivery, Int J Pharm, 455 (2013) 241-247.
175. Sharma K., Somavarapu S., Colombani A., Govind N., Taylor K.M.G., Crosslinked chitosan nanoparticle formulations for delivery from pressurized metered dose inhalers, European Journal of Pharmaceutics and Biopharmaceutics, 81 (2012) 74-81.
176. Shoyele S.A., Slowey A., Prospects of formulating proteins/ peptides as aerosols for pulmonary drug delivery, International journal of pharmaceutics, 314 (2006) 1-8.
177. Sinsuebpol C., Chatchawalsaisin J., Kulvanich P., Preparation and in vivo absorption evaluation of spray dried powders containing salmon calcitonin loaded chitosan nanoparticles for pulmonary delivery, Drug Design, Development and Therapy, 7 (2013) 861-873.
178. Snell N., Ganderton D., Assessing lung deposition of inhaled medications: Consensus statement from a workshop of the British Association for Lung Research, held at the Institute of Biology, London, U.K. on 17 April 1998, Respiratory medicine, 93 (1999) 123-133.
179. Son Y.J., Mcconville J.T., Development of a standardized dissolution test method for inhaled pharmaceutical formulations, Int J Pharm, 382 (2009) 15-22.
180. Sood B.G., Shen Y., Latif Z., Chen X., Sharp J., Neelavalli J., Joshi A., Slovis T.L., Haacke E., Aerosol delivery in ventilated newborn pigs: An MRI evaluation, Pediatric research, 64 (2008) 159-164.
181. Sood B.G., Shen Y., Latif Z., Galli B., Dawe E.J., Haacke E.M., Effective aerosol delivery during high-frequency ventilation in neonatal pigs, Respirology, 15 (2010) 551-555.
182. Sorrentino S., Human extracellular ribonucleases: Multiplicity, molecular diversity and catalytic properties of the major RNase types, Cell Mol Life Sci, 54 (1998) 785-794.
183. 129Xe contrast agents for magnetic resonance imaging, Current opinion in chemical biology, 14 (2010) 97-104.
184. Taylor K.M., Mccallion O.N., Ultrasonic nebulisers for pulmonary drug delivery, International journal of pharmaceutics, 153 (1997) 93-104.
185. Thomas C.E., Ehrhardt A., Kay M.A., Progress and problems with the use of viral vectors for gene therapy, Nature Reviews Genetics, 4 (2003) 346-358.
186. Thompson R.B., Finlay W.H., Using MRI to measure aerosol deposition, Journal of aerosol medicine and pulmonary drug delivery, 25 (2012) 55-62.
187. Tompkins S.M., Lo C.-Y., Tumpey T.M., Epstein S.L., Protection against lethal influenza virus challenge by RNA interference in vivo, Proceedings of the National Academy of Sciences of the United States of America, 101 (2004) 8682-8686.
188. Tronde A., Baran G., Eirefelt S., Lennernäs H., Bengtsson U.H., Miniaturized nebulization catheters: A new approach for delivery of defined aerosol doses to the rat lung, Journal of aerosol medicine, 15 (2002) 283-296.
189. Turner P.V., Brabb T., Pekow C., Vasbinder M.A., Administration of substances to laboratory animals: Routes of administration and factors to consider, Journal of the American Association for Laboratory Animal Science: JAALAS, 50 (2011) 600-613.
190. Wagner A., Vorauer-Uhl K., Katinger H., Nebulization of liposomal rh-Cu/Zn-SOD with a novel vibrating membrane nebulizer, Journal of liposome research, 16 (2006) 113-125.
191. Waldrep J., Dhand R., Advanced nebulizer designs employing vibrating mesh/aperture plate technologies for aerosol generation, Current Drug Delivery, 5 (2008) 114-119.
192. Wang H., Sebrié C., Ruaud J.P., Guillot G., Bouazizi-Verdier K., Willoquet G., Maître X., Darrasse L., De Rochefort L., Aerosol deposition in the lungs of spontaneously breathing rats using Gd-DOTA-based contrast agents and ultra-short echo time MRI at 1.5 tesla, Magnetic Resonance in Medicine, (2015).
193. Wang J.-C., Lai S., Guo X., Zhang X., De Crombrugghe B., Sonnylal S., Arnett F.C., Zhou X., Attenuation of fibrosis in vitro and in vivo with SPARC siRNA, Arthritis research & therapy, 12 (2010) R60.
194. Watts A.B., Mcconville J.T., Williams Iii R.O., Current therapies and technological advances in aqueous aerosol drug delivery, Drug development and industrial pharmacy, 34 (2008) 913-922.
195. Weinberger B., Sinko P.J., Laskin J.D., Laskin D.L., Interaction with lung macrophages, Nanoparticles in the Lung: Environmental Exposure and Drug Delivery, (2014) 85.
196. Xenariou S., Griesenbach U., Ferrari S., Dean P., Scheule R., Cheng S., Geddes D., Plank C., Alton E., Using magnetic forces to enhance non-viral gene transfer to airway epithelium in vivo, Gene therapy, 13 (2006) 1545-1552.
197. Xenariou S., Griesenbach U., Liang H., Zhu J., Farley R., Somerton L., Singh C., Jeffery P., Ferrari S., Scheule R., Use of ultrasound to enhance nonviral lung gene transfer in vivo, Gene therapy, 14 (2007) 768-774.
198. Yacobi N.R., Malmstadt N., Fazlollahi F., Demaio L., Marchelletta R., Hamm-Alvarez S.F., Borok Z., Kim K.-J., Crandall E.D., Mechanisms of alveolar epithelial translocation of a defined population of nanoparticles, American journal of respiratory cell and molecular biology, 42 (2010) 604-614.
199. Yang W., Peters J.I., Williams R.O., 3rd, Inhaled nanoparticles-a current review, Int J Pharm, 356 (2008) 239-247.
200. Yi D., Price A., Panoskaltsis-Mortari A., Naqwi A., Wiedmann T.S., Measurement of the distribution of aerosols among mouse lobes by fluorescent imaging, Analytical biochemistry, 403 (2010) 88-93.
201. Yoon S.H., Goo J.M., Lee S.M., Park C.M., Seo H.J., Cheon G.J., Positron emission tomography/magnetic resonance imaging evaluation of lung cancer: Current status and future prospects, Journal of thoracic imaging, 29 (2014) 4-16.
202. Yoshiyama Y., Yazaki T., Arai M., Asai K., Kanke M., The nebulization of budesonide suspensions by a newly designed mesh nebulizer, Respiratory drug delivery VIII. Raleigh: Davis Horwood, (2002) 487-489.
203. Zamora-Avila D., Zapata-Benavides P., Franco-Molina M., Saavedra-Alonso S., Trejo-Avila L., Resendez-Perez D., Mendez-Vazquez J., Isaias-Badillo J., Rodriguez-Padilla C., WT1 gene silencing by aerosol delivery of PEI-RNAi complexes inhibits B16-F10 lung metastases growth, Cancer gene therapy, 16 (2009) 892-899.
204. Zamora M.R., Budev M., Rolfe M., Gottlieb J., Humar A., Devincenzo J., Vaishnaw A., Cehelsky J., Albert G., Nochur S., Gollob J.A., Glanville A.R., RNA interference therapy in lung transplant patients infected with respiratory syncytial virus, Am J Respir Crit Care Med, 183 (2011) 531-538.
205. Zhang J., Wu L., Chan H.-K., Watanabe W., Formation, characterization, and fate of inhaled drug nanoparticles, Advanced drug delivery reviews, 63 (2011) 441-455.
206. Zhang X., Shan P., Jiang D., Noble P.W., Abraham N.G., Kappas A., Lee P.J., Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis, Journal of Biological Chemistry, 279 (2004) 10677-10684.
207. Zhao F., Zhao Y., Liu Y., Chang X., Chen C., Zhao Y., Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials, Small, 7 (2011) 1322-1337.